TCT 2022 – Edwards tries to Clasp an opportunity
The Pascal valve repair device boasts a pivotal hit and US approval, but can it compete?
Covid-19 takes its toll on medtechs’ efficiency
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
TCT 2021 – Medtronic and Edwards target hard-to-reach valves
Transcatheter technologies could be the future – but a distant one.
Aortic opportunity remains narrow for Abbott
Abbott’s latest aortic valve launch is unlikely to gain it a meaningful slice of the market; meanwhile, Edwards’ attention has switched to tricuspid.
Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Boston deadheads its Lotus
Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
Medtechs that book the most sales per employee face the greatest losses
Welcome to the calm before the Covid-19 storm.